Back to top
more

Moderna, Inc. (MRNA)

(Real Time Quote from BATS)

$198.80 USD

198.80
1,847,304

-3.67 (-1.81%)

Updated Jun 18, 2021 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (213 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US

Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

Moderna (MRNA) closed at $197.84 in the latest trading session, marking a -1.86% move from the prior day.

Neena Mishra headshot

Should You Buy Biotech ETFs Now?

Biotech stocks are rallying this month; can the trend continue?

Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.

AstraZeneca (AZN) COVID-19 Jab's New Side Effect Stated by EMA

The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.

Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks

Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate. Shares fall.

Indrajit Bandyopadhyay headshot

COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart

The CDC reports cases of myocarditis and pericarditis following inoculation with mRNA vaccines of Moderna (MRNA) and Pfizer (PFE). The authority schedules meeting next week to investigate these reports.

Sweta Jaiswal, FRM headshot

ETFs to Win as Moderna Seeks COVID-19 Vaccine Nod for Teens

Moderna (MRNA) is once again in the spotlight with an impressive update relating to mRNA-1273.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $217 in the latest trading session, marking a -0.2% move from the prior day.

The Zacks Analyst Blog Highlights: Amazon, Tesla, UnitedHealth Group, T-Mobile and Moderna

The Zacks Analyst Blog Highlights: Amazon, Tesla, UnitedHealth Group, T-Mobile and Moderna

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

Smart Beta ETF report for FAD

Sheraz Mian headshot

Top Research Reports for Amazon, Tesla & UnitedHealth

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Tesla (TSLA), and UnitedHealth Group (UNH).

Moderna (MRNA) Seeks Approval for COVID-19 Vaccine in Teens

Moderna (MRNA) is seeking authorization for conditional use of its COVID-19 vaccine, mRNA-1273, in adolescents in Europe and Canada.

Stock Market News for Jun 8, 2021

Benchmarks closed mixed on Monday as investors waited for more economic data to determine the course of economic recovery

Stock Market News for Jun 7, 2021

Benchmarks closed in the green on Friday as lesser-than-expected job additions eased concerns that the Federal Reserve might tighten monetary policies soon

Stock Market News for Jun 3, 2021

Wall Street closed marginally higher on Wednesday.

Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.

Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine

Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.

Benjamin Rains headshot

Find Strong Stocks with this First Profit Screener

The Zacks 'First Profit' screener is a solid place to start searching for strong stocks...

Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.

CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine

CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

Pfizer (PFE) COVID-19 Vaccine Gets Nod for Adolescents in EU

Pfizer (PFE)/BioNTech (BNTX) vaccine turns out to be 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.

Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study

Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.

Lumber Liquidators, Planet Fitness, Moderna, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day

Lumber Liquidators, Planet Fitness, Moderna, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day

Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Regeneron (REGN), among others.